Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer

• DOI: 10.3389/fgene.2021.673926
• Publication Date: 2021-07-09T09:01:45Z
• Authors: Xiaotong Duan; Simiao Qiao; Dianhe Li; Shangbiao Li; Zhihao Zheng; Qin Wang; Xiaoxia Zhu
• Keywords: KEGG; Fold change

Non-small cell lung cancer (NSCLC) accounts for about 85% of cancers. This study aimed to discover the potential miRNA biomarkers early detection NSCLC.Total circulating miRNAs were extracted from six patients and volunteers run on chip. The differentially expressed acquired by data mining intersected with chip results, qRT-PCR carried out. Then validated using a validation cohort (120 participants). ROC curves established evaluate diagnostic efficacy miRNAs. target genes differential identified miRTarBase database, follow-up GO KEGG enrichment analysis conducted.We 577 which screened according criteria (fold change > 2 p value < 0.05). Among them, seven passed additional filtering based mining. These further in training cohort. miR-492, miR-590-3p, miR-631 patients' serum, area under curve (AUC) values these 0.789, 0.792, 0.711, respectively. When them as combination discriminate healthy patients, AUC reached 0.828 (95% CI, 0.750-0.905, = 0.000) sensitivity 86.7% specificity 71.7%. showed that three associated tumorigenesis progression, such cycle P53 signaling pathway.The can be utilized distinguish individuals early-stage NSCLC patients.The might promising serum biomarker diagnosis NSCLC.